Cited by 4,148Cancer Immunotherapy and BiomarkersImmunotherapy and Immune ResponsesImmune cells in cancer

The DOI matches its Crossref record; 149 of the 149 references it cites were found in a registry or an index.

Innate and adaptive immune cells in the tumor microenvironment

Open access

Gajewski, Thomas F, Schreiber, Hans, Fu, Yang-Xin·2013·Nature Immunology

Open this paper in CoChat — free account

Abstract

Most tumor cells express antigens that can mediate recognition by host CD8(+) T cells. Cancers that are detected clinically must have evaded antitumor immune responses to grow progressively. Recent work has suggested two broad categories of tumor escape based on cellular and molecular characteristics of the tumor microenvironment. One major subset shows a T cell-inflamed phenotype consisting of infiltrating T cells, a broad chemokine profile and a type I interferon signature indicative of innate immune activation. These tumors appear to resist immune attack through the dominant inhibitory effects of immune system-suppressive pathways. The other major phenotype lacks this T cell-inflamed phenotype and appears to resist immune attack through immune system exclusion or ignorance. These two major phenotypes of tumor microenvironment may require distinct immunotherapeutic interventions for maximal therapeutic effect.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1038/ni.2703

Cites

149 of 149 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

1 retracted

FOXO3 programs tumor-associated DCs to become tolerogenic in human and murine prostate cancer
Watkins, S. K., Zhu, Z., Riboldi, E., Shafer-Weaver, K., Stagliano, K. E., Sklavos, M. M., Ambs, S., Yagita∥, H., & Hurwitz, A. A. (2011) · Journal of Clinical Investigation · doi:10.1172/jci44325 · Cited by 137
Retracted
Improved Survival with Ipilimumab in Patients with Metastatic Melanoma
Hodi, F. S., O'Day, S. J., McDermott, D. F., Weber, R. W., Sosman, J. A., Haanen, J. B., Gonzalez, R., Robert, C., Schadendorf, D., Hassel, J. C., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1003466 · Cited by 15,155
Safety, activity, and immune correlates of anti–PD-1 antibody in cancer
Topalian, S. L., Hodi, F. S., Brahmer, J. R., Gettinger, S. N., Smith, D. C., McDermott, D. F., Powderly, J. D., Carvajal, R. D., Sosman, J. A., Atkins, M. B., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1200690 · Cited by 12,628
Mutations of the BRAF gene in human cancer
Davies, H., Bignell, G. R., Cox, C., Stephens, P., Edkins, S., Clegg, S., Teague, J., Woffendin, H., Garnett, M. J., Bottomley, W., et al. (2002) · Nature · doi:10.1038/nature00766 · Cited by 10,674
Safety and activity of anti-PD-L1 antibody in patients with advanced cancer
Brahmer, J. R., Tykodi, S. S., Chow, L. Q. M., Hwu, W.-J., Topalian, S. L., Hwu, P., Drake, C. G., Camacho, L. H., Kauh, J., Odunsi, K., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1200694 · Cited by 7,945
Type, Density, and Location of Immune Cells Within Human Colorectal Tumors Predict Clinical Outcome
Galon, J., Costes, A., Sanchez-Cabo, F., Kirilovsky, A., Mlecnik, B., Lagorce-Pagès, C., Tosolini, M., Camus, M., Berger, A., Wind, P., et al. (2006) · Science · doi:10.1126/science.1129139 · Cited by 6,516
Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival
Curiel, T. J., Coukos, G., Zou, L., Alvarez, X., Cheng, P., Mottram, P., Evdemon-Hogan, M., Conejo-Garcia, J. R., Zhang, L., Burow, M., et al. (2004) · Nature Medicine · doi:10.1038/nm1093 · Cited by 5,151
Induction of Intestinal Th17 Cells by Segmented Filamentous Bacteria
Ivanov, I. I., Atarashi, K., Manel, N., Brodie, E. L., Shima, T., Karaoz, U., Wei, D., Goldfarb, K. C., Santee, C. A., Lynch, S. V., et al. (2009) · Cell · doi:10.1016/j.cell.2009.09.033 · Cited by 4,554
A Gene Encoding an Antigen Recognized by Cytolytic T Lymphocytes on a Human Melanoma
van der Bruggen, P., Traversari, C., Chomez, P., Lurquin, C., Plaen, E. D., den Eynde, B. J. V., Knuth, A. K., & Boon, T. (1991) · Science · doi:10.1126/science.1840703 · Cited by 3,548
Intratumoral T Cells, Recurrence, and Survival in Epithelial Ovarian Cancer
Zhang, L., Conejo-Garcia, J. R., Katsaros, D., Gimotty, P. A., Massobrio, M., Regnani, G., Makrigiannakis, A., Gray, H., Schlienger, K., Liebman, M. N., et al. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa020177 · Cited by 3,397

Flagged first, then by citations

Show all 149 references

Research works printed but not linked: 1

Spranger, S. et al. Upregulation of PD-L1, IDO and Tregs in the melanoma tumor microenvironment is driven by CD8+ T cells. Sci. Transl. Med. (in the press).

Sorted by citations

Items 301–400 of 1,004

Rationale for combination of therapeutic antibodies targeting tumor cells and immune checkpoint receptors: Harnessing innate and adaptive immunity through IgG1 isotype immune effector stimulation
Ferris, R. L., Lenz, H., Trotta, A. M., García‐Foncillas, J., Schulten, J., Audhuy, F., Merlano, M. C., & Milano, G. A. (2017) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2017.11.008 · Cited by 193
Extrinsic Phagocyte-Dependent STING Signaling Dictates the Immunogenicity of Dying Cells
Ahn, J., Xia, T., Rabasa, A., Betancourt, D. M., & Barber, G. N. (2018) · Cancer Cell · doi:10.1016/j.ccell.2018.03.027 · Cited by 194
CCL2: An Important Mediator Between Tumor Cells and Host Cells in Tumor Microenvironment
Jin, J., Lin, J., Xu, A., Lou, J., Qian, C., Li, X., Wang, Y., Yu, W., & Tao, H. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.722916 · Cited by 191
Epigenetics and immunotherapy: The current state of play
Dunn, J., & Rao, S. (2017) · Molecular Immunology · doi:10.1016/j.molimm.2017.04.012 · Cited by 192
NLRP3 inflammasome-mediated cytokine production and pyroptosis cell death in breast cancer
Faria, S. S., Costantini, S., de Lima, V. C. C., Andrade, V. P., Rialland, M., Rébé, C., Budillon, A., & Magalhães, K. G. (2021) · Journal of Biomedical Science · doi:10.1186/s12929-021-00724-8 · Cited by 192
Combining antibody–drug conjugates and immune-mediated cancer therapy: What to expect?
Gerber, H., Sapra, P., Loganzo, F., & May, C. (2015) · Biochemical Pharmacology · doi:10.1016/j.bcp.2015.12.008 · Cited by 188
Snail-overexpressing Cancer Cells Promote M2-Like Polarization of Tumor-Associated Macrophages by Delivering MiR-21-Abundant Exosomes
Hsieh, C.-H., Tai, S., & Yang, M. (2018) · Neoplasia · doi:10.1016/j.neo.2018.06.004 · Cited by 188
Generation of monocyte-derived tumor-associated macrophages using tumor-conditioned media provides a novel method to study tumor-associated macrophages in vitro
Benner, B. N., Scarberry, L., Suarez‐Kelly, L. P., Duggan, M. C., Campbell, A. R., Smith, E., Lapurga, G., Jiang, K., Butchar, J. P., Tridandapani, S., et al. (2019) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-019-0622-0 · Cited by 188
Combined intracavitary thermotherapy with iron oxide nanoparticles and radiotherapy as local treatment modality in recurrent glioblastoma patients
Grauer, O. M., Jaber, M., Heß, K., Weckesser, M., Schwindt, W., Maring, S., Wölfer, J., & Stummer, W. (2018) · Journal of Neuro-Oncology · doi:10.1007/s11060-018-03005-x · Cited by 186
Hallmarks of glioblastoma: a systematic review
Nørøxe, D. S., Poulsen, H. S., & Lassen, U. (2016) · ESMO Open · doi:10.1136/esmoopen-2016-000144 · Cited by 189
Immunomodulatory and antitumor effects of type I interferons and their application in cancer therapy
Medrano, R. F. V., Hunger, A., Mendonça, S. A., Barbuto, J. A. M., & Strauss, B. E. (2017) · Oncotarget · doi:10.18632/oncotarget.19531 · Cited by 192
Bispecific antibody based therapeutics: Strengths and challenges
Thakur, A. B., Huang, M. T. F., & Lum, L. G. (2018) · Blood Reviews · doi:10.1016/j.blre.2018.02.004 · Cited by 187
Immunomodulation by ionizing radiation—impact for design of radio‐immunotherapies and for treatment of inflammatory diseases
Frey, B., Rückert, M., Deloch, L., Rühle, P. F., Derer, A., Fietkau, R., & Gaipl, U. S. (2017) · Immunological Reviews · doi:10.1111/imr.12572 · Cited by 189
Nanoparticle‐Mediated Radiotherapy Remodels the Tumor Microenvironment to Enhance Antitumor Efficacy
Zhen, W., Weichselbaum, R. R., & Lin, W. (2022) · Advanced Materials · doi:10.1002/adma.202206370 · Cited by 188
Cancer-cell-derived fumarate suppresses the anti-tumor capacity of CD8+ T cells in the tumor microenvironment
Cheng, J., Yan, J., Liu, Y., Shi, J., Wang, H., Zhou, H., Zhou, Y., Zhang, T., Zhao, L., Meng, X., et al. (2023) · Cell Metabolism · doi:10.1016/j.cmet.2023.04.017 · Cited by 189
Targeting the T-Cell Co-stimulatory CD27/CD70 Pathway in Cancer Immunotherapy: Rationale and Potential
van de Ven, K., & Borst, J. G. (2015) · Immunotherapy · doi:10.2217/imt.15.32 · Cited by 184
Bioactive Compounds: Natural Defense Against Cancer?
Subramaniam, S., Selvaduray, K. R., & Radhakrishnan, A. K. (2019) · Biomolecules · doi:10.3390/biom9120758 · Cited by 183
Liposome-Based Drug Delivery Systems in Cancer Immunotherapy
Gu, Z., Silva, C. G. D., van der Maaden, K., OSSENDORP, F. A., & Cruz, L. J. (2020) · Pharmaceutics · doi:10.3390/pharmaceutics12111054 · Cited by 181
Technological advances in cancer immunity: from immunogenomics to single‐cell analysis and artificial intelligence
Xu, Y., Su, G.-H., Ma, D., Xiao, Y., Shao, Z.-M., & Jiang, Y.-Z. (2021) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-021-00729-7 · Cited by 163
“22,119 Therefore, characterizing the TIME and determining the cellular components could be highly bene ﬁ cial for tumor immunity studies.”
BackgroundMethod
PSGL-1 Is an Immune Checkpoint Regulator that Promotes T Cell Exhaustion
Tinoco, R., Carrette, F., Henriquez, M. L., Otero, D. C., Magaña, J., Bosenberg, M., Swain, S. L., & Bradley, L. M. (2016) · Immunity · doi:10.1016/j.immuni.2016.04.015 · Cited by 179
In situ vaccination by radiotherapy to improve responses to anti-CTLA-4 treatment
Vanpouille‐Box, C., Pilones, K. A., Wennerberg, E., Formenti, S. C., & Demaria, S. (2015) · Vaccine · doi:10.1016/j.vaccine.2015.05.105 · Cited by 180
Multiscale Agent-Based and Hybrid Modeling of the Tumor Immune Microenvironment
Norton, K., Gong, C., Jamalian, S., & Popel, A. S. (2019) · Processes · doi:10.3390/pr7010037 · Cited by 178
Autologous iPSC-Based Vaccines Elicit Anti-tumor Responses In Vivo
Kooreman, N. G., Kim, Y., de Almeida, P. E., Termglinchan, V., Diecke, S., Shao, N., Wei, T.-T., Yi, H., Dey, D., Nelakanti, R. V., et al. (2018) · Cell stem cell · doi:10.1016/j.stem.2018.01.016 · Cited by 173
TGF-beta signal transduction: biology, function and therapy for diseases
Tie, Y., Tang, F., Peng, D., Zhang, Y., & Shi, H. (2022) · Molecular Biomedicine · doi:10.1186/s43556-022-00109-9 · Cited by 186
Effects of Chemotherapy on the Immune System: Implications for Cancer Treatment and Patient Outcomes
Sharma, A., Jasrotia, S., & Kumar, A. (2023) · Naunyn-Schmiedeberg s Archives of Pharmacology · doi:10.1007/s00210-023-02781-2 · Cited by 190
Future perspectives in melanoma research
Ascierto, P. A., Agarwala, S. S., Botti, G., Cesano, A., Ciliberto, G., Davies, M. A., Demaria, S., Dummer, R., Eggermont, A. M. M., Ferrone, S., et al. (2016) · Journal of Translational Medicine · doi:10.1186/s12967-016-1070-y · Cited by 176
Self-citation
Distinctive features of tumor-infiltrating γδ T lymphocytes in human colorectal cancer
Meraviglia, S., Presti, E. L., Tosolini, M., Mendola, C. L., Orlando, V., Todaro, M., Catalano, V., Stassi, G., Cicero, G., Vieni, S., et al. (2017) · OncoImmunology · doi:10.1080/2162402x.2017.1347742 · Cited by 178
KDM5 histone demethylases repress immune response via suppression of STING
Wu, L., Cao, J. P., Cai, W. L., Lang, S. M., Horton, J. R., Jansen, D. J., Liu, Z. Z., Chen, J. F.-Y., Zhang, M., Mott, B. T., et al. (2018) · PLoS Biology · doi:10.1371/journal.pbio.2006134 · Cited by 182
Saikosaponin A Inhibits Breast Cancer by Regulating Th1/Th2 Balance
Zhao, X., Liu, J., Ge, S., Chen, C., Li, S., Wu, X., Feng, X., Wang, Y., & Cai, D. (2019) · Frontiers in Pharmacology · doi:10.3389/fphar.2019.00624 · Cited by 173
Astragalus polysaccharides (PG2) Enhances the M1 Polarization of Macrophages, Functional Maturation of Dendritic Cells, and T Cell-Mediated Anticancer Immune Responses in Patients with Lung Cancer
Bamodu, O. A., Kuo, K.-T., Wang, C., Huang, W.-C., Wu, A. T. H., Tsai, J.-T., Lee, K.-Y., Yeh, C., & Wang, L.-S. (2019) · Nutrients · doi:10.3390/nu11102264 · Cited by 174
Targeting a scavenger receptor on tumor-associated macrophages activates tumor cell killing by natural killer cells
Eisinger, S., Sarhan, D., Boura, V. F., Ibarlucea-Benitez, I., Tyystjärvi, S., Oliynyk, G., Arsenian‐Henriksson, M., Lane, D. P., Wickström, S. L., Kiessling, R. W., et al. (2020) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2015343117 · Cited by 180
Quantitative Spatial Profiling of PD-1/PD-L1 Interaction and HLA-DR/IDO-1 Predicts Improved Outcomes of Anti–PD-1 Therapies in Metastatic Melanoma
Johnson, D. B., Bordeaux, J., Kim, J. Y., Vaupel, C., Rimm, D. L., Ho, T. H., Joseph, R. W., DAUD, A. I., Conry, R. M., Gaughan, E. M., et al. (2018) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-18-0309 · Cited by 177
Cancer cell-intrinsic XBP1 drives immunosuppressive reprogramming of intratumoral myeloid cells by promoting cholesterol production
Yang, Z., Huo, Y., Zhou, S., Guo, J., Ma, X., Li, T., Fan, C., & Wang, L. (2022) · Cell Metabolism · doi:10.1016/j.cmet.2022.10.010 · Cited by 178
Genetic evolution of T-cell resistance in the course of melanoma progression
Sucker, A., Zhao, F., Real, B., Heeke, C., Bielefeld, N., Maβen, S., Horn, S., Moll, I., Maltaner, R., Horn, P. A., et al. (2014) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-0567 · Cited by 171
Fucosylated Antigens in Cancer: An Alliance toward Tumor Progression, Metastasis, and Resistance to Chemotherapy
Blanas, A., Sahasrabudhe, N. M., Rodríguez, E., van Kooyk, Y., & van Vliet, S. J. (2018) · Frontiers in Oncology · doi:10.3389/fonc.2018.00039 · Cited by 172
Inflammation in Wound Healing and Pathological Scarring
Hong, Y., Chang, Y., Lin, Y., Chen, B., Guevara, B. E. K., & Hsu, C.-K. (2022) · Advances in Wound Care · doi:10.1089/wound.2021.0161 · Cited by 179
Intratumoral CD8+ T-cell Apoptosis Is a Major Component of T-cell Dysfunction and Impedes Antitumor Immunity
Horton, B. L., Williams, J. B., Cabanov, A., Spranger, S., & Gajewski, T. F. (2017) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-17-0249 · Cited by 170
Self-citation
Macrophage-Derived Granulin Drives Resistance to Immune Checkpoint Inhibition in Metastatic Pancreatic Cancer
Quaranta, V., Rainer, C., Nielsen, S. R., Raymant, M., Ahmed, M. S., Engle, D. D., Taylor, A., Murray, T., Campbell, F., Palmer, D. H., et al. (2018) · Cancer Research · doi:10.1158/0008-5472.can-17-3876 · Cited by 171
Cell-mediated targeting drugs delivery systems
Yu, H., Yang, Z., Li, F., Xu, L. X., & Sun, Y. (2020) · Drug Delivery · doi:10.1080/10717544.2020.1831103 · Cited by 171
Myeloid-Derived Suppressor Activity Is Mediated by Monocytic Lineages Maintained by Continuous Inhibition of Extrinsic and Intrinsic Death Pathways
Haverkamp, J. M., Smith, A. M., Weinlich, R., Dillon, C. P., Qualls, J. E., Neale, G. A. M., Koss, B. S., Kim, Y., Bronte, V., Herold, M. J., et al. (2014) · Immunity · doi:10.1016/j.immuni.2014.10.020 · Cited by 169
Prognostic Value of Macrophage Phenotypes in Resectable Non–Small Cell Lung Cancer Assessed by Multiplex Immunohistochemistry
Rakaee, M., Busund, L., Jamaly, S., Paulsen, E., Richardsen, E., Andersen, S., Al-Saad, S., Bremnes, R., Donnem, T., & Kilvaer, T. (2019) · Neoplasia · doi:10.1016/j.neo.2019.01.005 · Cited by 133
Inhibition of Rspo-Lgr4 Facilitates Checkpoint Blockade Therapy by Switching Macrophage Polarization
Tan, B., Shi, X., Zhang, J., Qin, J., Zhang, N., Ren, H., Qian, M., Siwko, S. K., Carmon, K. S., Liu, Q., et al. (2018) · Cancer Research · doi:10.1158/0008-5472.can-18-0152 · Cited by 166
Characterizing diversity in the tumor-immune microenvironment of distinct subclasses of gastroesophageal adenocarcinomas
Derks, S., de Klerk, L. K., Xu, X., Fleitas, T., Liu, K. X., Liu, Y., Dietlein, F., Margolis, C. A., Chiaravalli, A. M., Silva, A. C. D., et al. (2020) · Annals of Oncology · doi:10.1016/j.annonc.2020.04.011 · Cited by 166
Overcoming barriers to effective immunotherapy: MDSCs, TAMs, and Tregs as mediators of the immunosuppressive microenvironment in head and neck cancer
Davis, R. J., Waes, C. V., & Allen, C. T. (2016) · Oral Oncology · doi:10.1016/j.oraloncology.2016.05.002 · Cited by 167
The Relationship Between Dormant Cancer Cells and Their Microenvironment
Linde, N., Fluegen, G., & Aguirre‐Ghiso, J. A. (2016) · Advances in cancer research · doi:10.1016/bs.acr.2016.07.002 · Cited by 172
Harnessing non-destructive 3D pathology
Liu, J. T. C., Glaser, A. K., Bera, K., True, L. D., Reder, N. P., Eliceiri, K. W., & Madabhushi, A. (2021) · Nature Biomedical Engineering · doi:10.1038/s41551-020-00681-x · Cited by 160
Midkine rewires the melanoma microenvironment toward a tolerogenic and immune-resistant state
Cerezo‐Wallis, D., Contreras-Alcalde, M., Troulé, K., Catena, X., Mucientes, C., Calvo, T. G., Cañón, E., Tejedo, C., Pennacchi, P. C., Hogan, S. A., et al. (2020) · Nature Medicine · doi:10.1038/s41591-020-1073-3 · Cited by 168
Immune Response and the Tumor Microenvironment: How They Communicate to Regulate Gastric Cancer
Lee, K., Hwang, H. K., & Nam, K. T. (2014) · Gut and Liver · doi:10.5009/gnl.2014.8.2.131 · Cited by 159
PGE2 induced in and released by dying cells functions as an inhibitory DAMP
Hangai, S., Ao, T., Kimura, Y., Matsuki, K., Kawamura, T., Negishi, H., Nishio, J., Kodama, T., Taniguchi, T., & Yanai, H. (2016) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1602023113 · Cited by 168
Association of PD-1/PD-L axis expression with cytolytic activity, mutational load, and prognosis in melanoma and other solid tumors
Danilova, L., Wang, H., Sunshine, J. C., Kaunitz, G. J., Cottrell, T. R., Xu, H., Esandrio, J., Anders, R. A., Cope, L., Pardoll, D. M., et al. (2016) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1607836113 · Cited by 164
ER stress-induced mediator C/EBP homologous protein thwarts effector T cell activity in tumors through T-bet repression
Cao, Y., Trillo-Tinoco, J., Sierra, R. A., Anadon, C., Dai, W., Mohamed, E., Cen, L., Costich, T. L., Magliocco, A., Marchion, D., et al. (2019) · Nature Communications · doi:10.1038/s41467-019-09263-1 · Cited by 161
IDO1: An important immunotherapy target in cancer treatment
Li, F., Zhang, R., Li, S., & Liu, J. (2017) · International Immunopharmacology · doi:10.1016/j.intimp.2017.03.024 · Cited by 162
Immunotherapy for Head and Neck Squamous Cell Carcinoma
Moskovitz, J. M., Moy, J. D., & Ferris, R. L. (2018) · Current Oncology Reports · doi:10.1007/s11912-018-0654-5 · Cited by 164
Leutusome: A Biomimetic Nanoplatform Integrating Plasma Membrane Components of Leukocytes and Tumor Cells for Remarkably Enhanced Solid Tumor Homing
He, H., Guo, C., Wang, J., Korzun, W. J., Wang, X., Ghosh, S., & Yang, H. (2018) · Nano Letters · doi:10.1021/acs.nanolett.8b01892 · Cited by 161
Nanoformulated Codelivery of Quercetin and Alantolactone Promotes an Antitumor Response through Synergistic Immunogenic Cell Death for Microsatellite-Stable Colorectal Cancer
Zhang, J., Shen, L., Li, X., Song, W., Liu, Y., & Huang, L. (2019) · ACS Nano · doi:10.1021/acsnano.9b02875 · Cited by 159
Polypyrrole Nanoenzymes as Tumor Microenvironment Modulators to Reprogram Macrophage and Potentiate Immunotherapy
Zeng, W., Yu, M., Chen, T., Liu, Y., Yi, Y., Huang, C., Tang, J., Li, H., Ou, M., Wang, T., et al. (2022) · Advanced Science · doi:10.1002/advs.202201703 · Cited by 159
Metal-organic framework nanoagent induces cuproptosis for effective immunotherapy of malignant glioblastoma
Huang, Q., Liang, J., Chen, Q., Jin, X., Niu, M., Dong, C., & Zhang, X. (2023) · Nano Today · doi:10.1016/j.nantod.2023.101911 · Cited by 162
Established T Cell–Inflamed Tumors Rejected after Adaptive Resistance Was Reversed by Combination STING Activation and PD-1 Pathway Blockade
Moore, E. C., Clavijo, P. E., Davis, R. J., Cash, H. A., Waes, C. V., Kim, Y., & Allen, C. T. (2016) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-16-0104 · Cited by 158
Heparanase and the hallmarks of cancer
Jayatilleke, K. M., & Hulett, M. D. (2020) · Journal of Translational Medicine · doi:10.1186/s12967-020-02624-1 · Cited by 167
Bioinspired and Biomimetic Delivery Platforms for Cancer Vaccines
Liu, J., Liew, S. S., Wang, J., & Pu, K. (2021) · Advanced Materials · doi:10.1002/adma.202103790 · Cited by 161
Tumor Microenvironment Remodeling by Intratumoral Oncolytic Vaccinia Virus Enhances the Efficacy of Immune-Checkpoint Blockade
Chon, H. J., Lee, W. S., Yang, H., Kong, S. J., Lee, N. K., Moon, E. S., Choi, J., Han, E. C., Kim, J. H., Ahn, J. B., et al. (2019) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-18-1932 · Cited by 158
Titin mutation associated with responsiveness to checkpoint blockades in solid tumors
Jia, Q., Wang, J., He, N., He, J., & Zhu, B. (2019) · JCI Insight · doi:10.1172/jci.insight.127901 · Cited by 162
Nanobiomaterial-based vaccination immunotherapy of cancer
Chen, F., Wang, Y., Gao, J., Saeed, M., Li, T., Wang, W., & Yu, H. (2021) · Biomaterials · doi:10.1016/j.biomaterials.2021.120709 · Cited by 159
Nanoliposome C6-Ceramide Increases the Anti-tumor Immune Response and Slows Growth of Liver Tumors in Mice
Li, G., Liu, D., Kimchi, E. T., Kaifi, J. T., Qi, X., Manjunath, Y., Liu, X., Deering, T. G., Avella, D. M., Fox, T. E., et al. (2018) · Gastroenterology · doi:10.1053/j.gastro.2017.10.050 · Cited by 157
Phase Ib study of the combination of pexidartinib (PLX3397), a CSF-1R inhibitor, and paclitaxel in patients with advanced solid tumors
Wesolowski, R., Sharma, N., Reebel, L., Rodal, M. B., Alexandra, P., West, B. L., Marimuthu, A., Severson, P. L., Karlin, D. A., Dowlati, A., et al. (2019) · Therapeutic Advances in Medical Oncology · doi:10.1177/1758835919854238 · Cited by 158
Biomimetic Nanoemulsion for Synergistic Photodynamic‐Immunotherapy Against Hypoxic Breast Tumor
Zhang, Y., Liao, Y., Tang, Q., Lin, J., & Huang, P. (2021) · Angewandte Chemie International Edition · doi:10.1002/anie.202015590 · Cited by 157
Harnessing T cells to fight cancer with BiTE® antibody constructs – past developments and future directions
Klinger, M., Benjamin, J., Kischel, R., Stienen, S., & Zugmaier, G. (2016) · Immunological Reviews · doi:10.1111/imr.12393 · Cited by 157
Subtypes of HPV-Positive Head and Neck Cancers Are Associated with HPV Characteristics, Copy Number Alterations, PIK3CA Mutation, and Pathway Signatures
Zhang, Y., Koneva, L. A., Virani, S., Arthur, A. E., Virani, A., Hall, P. B., Warden, C., Carey, T. E., Chepeha, D. B., Prince, M. E., et al. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-16-0323 · Cited by 154
Tumor-targeted delivery of sunitinib base enhances vaccine therapy for advanced melanoma by remodeling the tumor microenvironment
Huo, M., Zhao, Y., Satterlee, A., Wang, Y., Xu, Y., & Huang, L. (2016) · Journal of Controlled Release · doi:10.1016/j.jconrel.2016.11.013 · Cited by 156
Complementing Cancer Photodynamic Therapy with Ferroptosis through Iron Oxide Loaded Porphyrin-Grafted Lipid Nanoparticles
Liang, X., Chen, M., Bhattarai, P., Hameed, S., Tang, Y., & Dai, Z. (2021) · ACS Nano · doi:10.1021/acsnano.1c08108 · Cited by 156
A new emerging target in cancer immunotherapy: Galectin-9 (LGALS9)
Lv, Y., Ma, X., Ma, Y., Du, Y., & Feng, J. (2022) · Genes & Diseases · doi:10.1016/j.gendis.2022.05.020 · Cited by 159
Nanovaccine based on a protein-delivering dendrimer for effective antigen cross-presentation and cancer immunotherapy
Xu, J., Wang, H., Xu, L., Chao, Y., Wang, C., Han, X., Dong, Z., Chang, H., Peng, R., Cheng, Y., et al. (2019) · Biomaterials · doi:10.1016/j.biomaterials.2019.03.037 · Cited by 155
Advancements in prophylactic and therapeutic nanovaccines
Bhardwaj, P., Bhatia, E., Sharma, S., Ahamad, N., & Banerjee, R. (2020) · Acta Biomaterialia · doi:10.1016/j.actbio.2020.03.020 · Cited by 156
Pre-clinical and clinical importance of miR-21 in human cancers: Tumorigenesis, therapy response, delivery approaches and targeting agents
Hashemi, M., Mirdamadi, M. S. A., Talebi, Y., Khaniabad, N., Banaei, G., Daneii, P., Gholami, S., Ghorbani, A., Tavakolpournegari, A., Farsani, Z. M., et al. (2023) · Pharmacological Research · doi:10.1016/j.phrs.2022.106568 · Cited by 153
Bioprinting of 3D breast epithelial spheroids for human cancer models
Swaminathan, S., Hamid, Q., Sun, W., & Clyne, A. M. (2019) · Biofabrication · doi:10.1088/1758-5090/aafc49 · Cited by 154
Molecular subtyping of cancer: current status and moving toward clinical applications
Zhao, L., Lee, V. H.-F., Ng, M. K., Yan, H., & Bijlsma, M. F. (2018) · Briefings in Bioinformatics · doi:10.1093/bib/bby026 · Cited by 156
Reactive Oxygen Species and Antitumor Immunity—From Surveillance to Evasion
Kotsafti, A., Scarpa, M., Castagliuolo, I., & Scarpa, M. (2020) · Cancers · doi:10.3390/cancers12071748 · Cited by 161
Molecular mechanisms of the preventable causes of cancer in the United StatesPreprint
Golemis, E. A., Scheet, P. A., Beck, T. N., Scolnick, E. M., Hunter, D. J., Hawk, E. T., & Hopkins, N. H. (2018) · Genes & Development · doi:10.1101/gad.314849.118 · Cited by 164
Lighting a Fire in the Tumor Microenvironment Using Oncolytic Immunotherapy
Achard, C., Surendran, A., Wedge, M.-È., Ungerechts, G., Bell, J. C., & Ilkow, C. S. (2018) · EBioMedicine · doi:10.1016/j.ebiom.2018.04.020 · Cited by 163
Tumor Suppressor miRNA-204-5p Regulates Growth, Metastasis, and Immune Microenvironment Remodeling in Breast Cancer
Hong, B. S., Ryu, H. S., Kim, N., Kim, J., Lee, E.-S., Moon, H., Kim, K. H., Jin, M., Kwon, N. H., Kim, S., et al. (2019) · Cancer Research · doi:10.1158/0008-5472.can-18-0891 · Cited by 155
AIEgen-coupled upconversion nanoparticles eradicate solid tumors through dual-mode ROS activation
Mao, D., Hu, F., Yi, Z., Kenry, K., Xu, S., Yan, S., Luo, Z., Wu, W., Wang, Z., Kong, D., et al. (2020) · Science Advances · doi:10.1126/sciadv.abb2712 · Cited by 153
Cancer Treatment with Anti-PD-1/PD-L1 Agents: Is PD-L1 Expression a Biomarker for Patient Selection?
Festino, L., Botti, G., Lorigan, P. C., Masucci, G. V., Hipp, J., Horak, C. E., Melero, I., & Ascierto, P. A. (2016) · Drugs · doi:10.1007/s40265-016-0588-x · Cited by 149
Breast cancer genomics and immuno-oncological markers to guide immune therapies
Hammerl, D., Smid, M., Timmermans, A. M., Sleijfer, S., Martens, J. W. M., & Debets, R. (2017) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2017.11.003 · Cited by 157
Angiogenesis and the Tumor Microenvironment: Vascular Endothelial Growth Factor and Beyond
Mittal, K., Ebos, J. M. L., & Rini, B. I. (2014) · Seminars in Oncology · doi:10.1053/j.seminoncol.2014.02.007 · Cited by 153
High-throughput single-сell sequencing in cancer research
Jia, Q., Chu, H., Jin, Z., Long, H., & Zhu, B. (2022) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-022-00990-4 · Cited by 157
The interplay of effector and regulatory T cells in cancer
Roychoudhuri, R., Eil, R. L., & Restifo, N. P. (2015) · Current Opinion in Immunology · doi:10.1016/j.coi.2015.02.003 · Cited by 154
Supramolecular prodrug hydrogelator as an immune booster for checkpoint blocker–based immunotherapy
Wang, F., Xu, D., Su, H., Zhang, W., Sun, X., Monroe, M. K., Chakroun, R. W., Wang, Z., Dai, W., Oh, R., et al. (2020) · Science Advances · doi:10.1126/sciadv.aaz8985 · Cited by 152
RNA aggregates harness the danger response for potent cancer immunotherapy
Méndez‐Gómez, H. R., DeVries, A., Castillo, P., Roemeling, C. A. V., Qdaisat, S., Stover, B. D., Xie, C., Weidert, F. L., Zhao, C., Moor, R., et al. (2024) · Cell · doi:10.1016/j.cell.2024.04.003 · Cited by 162
Hypoxia-induced CCL28 promotes recruitment of regulatory T cells and tumor growth in liver cancer
Ren, L., Yu, Y., Wang, L., Zhu, Z., Lu, R., & Yao, Z. (2016) · Oncotarget · doi:10.18632/oncotarget.12409 · Cited by 149
Cancer-Associated Fibroblasts: Understanding Their Heterogeneity
Louault, K., Li, R., & DeClerck, Y. A. (2020) · Cancers · doi:10.3390/cancers12113108 · Cited by 162
mTOR Signaling, Tregs and Immune Modulation
Chapman, N. M., & Chi, H. (2014) · Immunotherapy · doi:10.2217/imt.14.84 · Cited by 148
Stromal infiltration of CD8 T cells is associated with improved clinical outcome in HPV-positive oropharyngeal squamous carcinoma
Oguejiofor, K., Hall, J., Slater, C., Betts, G. N. J., Hall, G. L., Slevin, N. J., Dovedi, S. J., Stern, P. L., & West, C. (2015) · British Journal of Cancer · doi:10.1038/bjc.2015.277 · Cited by 149
Correlation of metabolic information on FDG-PET with tissue expression of immune markers in patients with non-small cell lung cancer (NSCLC) who are candidates for upfront surgery
Lopci, E., Toschi, L., Grizzi, F., Rahal, D., Olivari, L., Castino, G. F., Marchetti, S., Cortese, N., Qehajaj, D., Pistillo, D., et al. (2016) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-016-3425-2 · Cited by 145
The Tumor Microenvironment in Tumorigenesis and Therapy Resistance Revisited
Dzobo, K., Senthebane, D. A., & Dandara, C. (2023) · Cancers · doi:10.3390/cancers15020376 · Cited by 146
Combining chemotherapy with PD-1 blockade in NSCLC
Mathew, M., Enzler, T., Shu, C. A., & Rizvi, N. A. (2018) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2018.01.003 · Cited by 147
A Four-Chemokine Signature Is Associated with a T-cell–Inflamed Phenotype in Primary and Metastatic Pancreatic Cancer
Romero, J. M., Grünwald, B., Jang, G.-H., Bavi, P. P., Jhaveri, A., Masoomian, M., Fischer, S. E., Zhang, A., Denroche, R. E., Lungu, I. M., et al. (2020) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-19-2803 · Cited by 146
Development and validation of an immune‐related prognostic signature in lung adenocarcinoma
Sun, S., Guo, W., Wang, Z., Wang, X., Zhang, G., Zhang, H., Li, R., Gao, Y., Qiu, B., Tan, F., et al. (2020) · Cancer Medicine · doi:10.1002/cam4.3240 · Cited by 142
Metabolism of Dendritic Cells in Tumor Microenvironment: For Immunotherapy
Peng, X., He, Y., Huang, J. X., Tao, Y., & Liu, S. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.613492 · Cited by 146
Tumor-intrinsic oncogene pathways mediating immune avoidance
Spranger, S., & Gajewski, T. F. (2015) · OncoImmunology · doi:10.1080/2162402x.2015.1086862 · Cited by 154
Self-citation
Dual Role of Macrophage in Tumor Immunity
Tamura, R., Tanaka, T., Yamamoto, Y., Akasaki, Y., & Sasaki, H. (2018) · Immunotherapy · doi:10.2217/imt-2018-0006 · Cited by 148

Authors: Gajewski, T. F., Schreiber, H., & Fu, Y.-X.
Affiliations: University of Chicago (US)
Corresponding author: Gajewski, Thomas F
ORCID: Schreiber, Hans
Fu, Yang-Xin
Venue: Nature Immunology
Publisher: Springer Science and Business Media LLC
Published: 2013-09-18
Volume: 14
Issue: 10
Pages: 1014-1022
ISSN: 1529-2908 (ISSN-L)
1529-2916
DOI: 10.1038/ni.2703
PMC: PMC4118725
OpenAlex: W2042699075
Cited by: 4,148
References: 149
Citations by year: 2026: 187 · 2025: 310 · 2024: 432 · 2023: 486 · 2022: 443 · 2021: 522 · 2020: 372 · 2019: 315 · 2018: 290 · 2017: 290 · 2016: 240 · 2015: 162 · 2014: 82 · 2013: 1
FWCI: 17.11
Type: journal article
Language: en
Open access: green
www.ncbi.nlm.nih.gov
Licence: www.springer.com/tdm (tdm)
Locations: Nature Immunology (publishedVersion)
PubMed (publishedVersion)
Europe PMC (PubMed Central) (acceptedVersion)
PubMed Central (acceptedVersion)
Funders: National Cancer Institute (R01CA161005, R01CA127475, R01CA118153)
Topics: Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
Life Sciences › Immunology and Microbiology › Immunology › Immune cells in cancer
Keywords: tumor microenvironment, tumor immune evasion, innate immunity, adaptive immunity, CD8+ T cells, immune exclusion, type I interferon signature, chemokine profile, immune checkpoint blockade, cancer immunotherapy
MeSH terms: Animals, Dendritic Cells, Humans, Immunity, Innate, Lymphocyte Activation, Neoplasms, T-Lymphocyte Subsets, Stromal Cells, Adaptive Immunity, Tumor Microenvironment

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Innate and adaptive immune cells in the tumor microenvironment

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks